Common Stock Dividends Paid (Quarterly)

Common Stock Dividends Paid: The cash outflow for dividends paid on a company's common stock.

BioXcel Therapeutics, Inc. (BTAI) Common Stock Dividends Paid data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$0.12M
Net Income	$-19.19M
Cost of Goods Sold	$0.11M
Gross Profit	$0.01M
Operating Expenses	$15.97M
Operating Income	$-15.85M
Non-Operating Income/Expense	$-3.33M
Pre-Tax Income	$-19.19M
Normalized Pre-Tax Income	$-19.19M
Income after Taxes	$-19.19M
Income from Continuous Operations	$-19.19M
Consolidated Net Income/Loss	$-19.19M
Normalized Income after Taxes	$-19.19M
EBIT	$-15.85M
EBITDA	$-15.78M
Weighted-Average Shares Outstanding (Basic)	7.84M
Weighted-Average Shares Outstanding (Diluted)	7.84M
Earnings per Share (EPS) (Basic)	$-2.45
Earnings per Share (EPS) (Diluted)	$-2.45
Balance Sheet Financials
Current Assets	$25.24M
Property, Plant, and Equipment	$0.32M
Long-Term Assets	$0.55M
Total Assets	$25.79M
Current Liabilities	$33.38M
Long-Term Debt	$97.47M
Long-Term Liabilities	$100.08M
Total Liabilities	$133.46M
Common Equity	$-107.67M
Tangible Shareholders Equity	$-107.67M
Shareholders Equity	$-107.67M
Common Shares Outstanding	6.62M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-24.62M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$13.34M
Beginning Cash	$29.85M
End Cash	$18.57M
Increase/Decrease in Cash	$-11.28M
Stock-Based Compensation	$1.74M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.76
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-9.56
Debt to Equity Ratio	-1.01
Gross Margin	10.83%
Operating Margin	-13210.00%
EBIT Margin	-13210.00%
EBITDA Margin	--
Pre-Tax Profit Margin	-15989.17%
Profit Margin	-15989.17%
Free Cash Flow	$-24.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.00
Inventory Turnover	0.21
Receiveable Turnover	7.06
Days Sales in Receivables	12.75
Return on Equity	17.82%
Return on Tangible Equity	17.82%
Return on Assets	-74.40%
Return on Investments	188.14%
Book Value Per Share	$-16.26
Free Cash Flow per Share	$-3.14
Operating Cash Flow per Share	$-3.14

Data from Zacks Investment Research, Inc.